Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia.
Preeclampsia is a leading cause of intrauterine growth restriction and preterm birth. Endothelial dysfunction is the common final pathway leading to clinical signs of preeclampsia including hypertension and proteinuria. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NOS and induces endothelial dysfunction by reversibly inhibiting NO production from l-arginine. The purpose of this study was to investigate maternal and fetal concentrations of ADMA, l-arginine, and symmetric dimethylarginine (SDMA). Women with preeclampsia (n = 47) and controls (n = 51) who gave birth by cesarean section were included in the study. We analyzed the maternal plasma and umbilical vein and artery plasma. We found that not only maternal concentrations of ADMA and SDMA but also l-arginine were significantly higher in women with preeclampsia than in controls. In fetal samples, only SDMA concentrations were higher in the preeclampsia group than in controls. The median ADMA concentration was three times higher in the fetal circulation than in the maternal circulation, but there was no difference between the preeclampsia group and the control group, and the veno-arterious gradient indicated that the placenta was the source of ADMA.
Braekke
Kristin
K
Department of Paediatrics, Ulleval University Hospital, Oslo 0407, Norway. kbre@uus.n
Ueland
Per M
PM
Harsem
Nina K
NK
Staff
Anne Cathrine
AC
D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D005333:Fetus / Q000098:blood supply / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009569:Nitric Oxide / Q000378:metabolism; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D055815:Young Adult
D009569:Nitric Oxide; C018524:N,N-dimethylarginine; D001120:Arginine